Management explicitly expects a "25% to 38% year over year" revenue decline in 2026, stating "the operating environment remains highly uncertain given clinician confusion surrounding CMS's comments on ...
Welcome, ladies and gentlemen, to the Fourth Quarter and Full Year 2025 Earnings Conference Call for Organogenesis Holdings, Inc. [Operator Instructions] Please note that this conference call is being ...
Francisco provided 2026 guidance, stating, "we expect total net revenue to decline in the range of 25% to 38% year-over-year for the full year 2026 period." He attributed this to ongoing market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results